Charcot-Marie-Tooth type 1A disease from patient to laboratory

Journal of the Pakistan Medical Association

Volumn 65, Issue 2, 2015, Pages 206-212

  Perveen, Shazia ^a   Mannan, Shazia ^b   Hussain, Abrar ^b   Kanwal, Sumaira ^b  

^a The Catholic University of Korea   (South Korea)

^b COMSATS Institute of Information Technology Sahiwal Campus ^*  (Pakistan)

Author keywords

Ascorbic acid; Charcot Marie Tooth disease; Demyelintion; Nerve conduction velocity; Peroneal dystrophy

Indexed keywords

CONNEXIN 32; DYNAMIN II; EARLY GROWTH RESPONSE FACTOR 2; GAP JUNCTION PROTEIN; GLYCINE TRANSFER RNA LIGASE; HEAT SHOCK PROTEIN; MITOFUSIN 2; MYELIN PROTEIN; PERIPHERAL MYELIN PROTEIN 22;

AUTOSOMAL DOMINANT INHERITANCE; BIBLIOGRAPHIC DATABASE; CHROMOSOME 17; CHROMOSOME DELETION; CHROMOSOME DUPLICATION; DEMYELINATION; GENE; GENE EXPRESSION; GENE MAPPING; GENE MUTATION; GENE SEQUENCE; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MOTOR NEUROPATHY; MUSCLE ACTION POTENTIAL; MUSCLE ATROPHY; NERVE CONDUCTION; NERVE POTENTIAL; NONHUMAN; PMP22 GENE; REVIEW; SCHWANN CELL; SENSORY DYSFUNCTION; SPINAL MUSCULAR ATROPHY; CHARCOT-MARIE-TOOTH DISEASE; GENETICS;

CHARCOT-MARIE-TOOTH DISEASE; HUMANS;

EID: 84928238588     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Charcot JM, Marie P. [Sur une forme particulière d'atrophie musculaire progressive, souvent familiale, debutant par les pieds et les jambes et atteignant plus tard les mains]. Rev Med 1886; 6: 97-138.
2. Tooth HH. The Peroneal Type of Progressive Muscular Atrophy. University of Cambridge, London: 1886
3. Braathen GJ, Sand JC, Lobato A, Høyer H, Russell MB. Genetic epidemiology of Charcot-Marie-Tooth in the general population. Eur J Neurol 2011; 18:39-48.
4. Dyck PJ, Lambert EH. Lower motor and primary sensory neuron diseases with peroneal muscular atrophy. I. Neurologic, genetic, and electrophysiologic findings in hereditary polyneuropathies. Arch Neurol 1968; 18: 603-18.
5. Kinga S, Lupski JR. Charcot-Marie-Tooth disease. Eur J Hum Genet 2009; 17: 703-10.
6. Reilly MM, Murphy SM, Laura M. Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2011; 16: 1-14.
7. Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain 1980; 103:259-80.
8. Timmerman V, Clowes VE, Reid E. Overlapping molecular pathological themes link Charcot-Marie-Tooth neuropathies and hereditary spastic paraplegias. Exp Neurol 2013; 246:14-25.
9. Reilly MM, Murphy SM, Laura M. Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2011; 16:1-14.
10. Saporta MA, Shy ME. Inherited peripheral neuropathies. Neurol Clin 2013; 31:597-619.
11. Truini A, Biasiotta A, La Cesa S, Di Stefano G, Galeotti F, Petrucci MT, et al. Mechanisms of pain in distal symmetric polyneuropathy: a combined clinical and neurophysiological study. Pain 2010; 150: 516-21.
12. Abe A, Nakamura K, Kato M, Numakura C, Honma T, Seiwa C, et al. Compound heterozygous PMP22 deletion mutations causing severe Charcot-Marie-Tooth disease type 1. J Hum Genet 2010; 55:771-3.
13. Kamholz J, Menichella D, Jani A. Charcot-Marie-Toothdisease type 1: molecular pathogenesis to gene therapy. Brain 2000; 123: 222-33.
14. Vincent T, Alleene V, Strickl SZ. Genetics of Charcot-Marie-Tooth (CMT) Disease within the Frame of the Human Genome Project Success. Genes 2014; 5: 13-32.
15. Bird TD, Ott J, Giblett ER. Evidence for linkage of Charcot-Marie- Tooth neuropathy to the Duffy locus on chromosome 1. AmJ Hum Genet 1982; 34:388-94.
16. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001; 291: 1304-51.
17. Ng SB, Buckingham KJ, Lee C, Bigham, AW, Tabor HK, Dent KM, et al. Exome sequencing identifies the cause of a mendelian disorder. Nat Genet 2010, 42: 30-5.
18. Akimoto C, Morita M, Yamamoto M, Nakano I. Novelmutation in Xlinked Charcot-Marie-tooth (CMTXI) disease associated with central conduction slowing on brainstem auditory evoked potential (BAEP). Rinsho Shinkeigaku 2010; 50: 399-403.
19. Lewis RA, Sumner AJ, Shy ME. Electrophysiological features of inherited demyelinating neuropathies: A reappraisal in the era of molecular diagnosis. Muscle Nerve 2000; 23, 1472-87.
20. Lupski J R, Wise CA, Kuwano A, Pentao L, Parke JT, Glaze DG, et al. Gene dosage is a mechanism for Charcot-Marie-Tooth disease type 1A. Nature Genet 1992; 1: 29-33.
21. Matise TC, Chakravarti A, Patel PI, Lupski JR, Nelis E, Timmerman V, et al. Detection of tandem duplications and implications for linkage analysis. Am J Hum Genet 1994; 54: 1110-21.
22. Schiavon, F, Mostacciuolo, ML, Saad, F, Merlini, L, Siciliano, G, Angelini, C, et al. Non-radioactive detection of 17p11.2 duplication in CMT1A: a study of 78 patients. J Med Genet 1994; 31: 880-3
23. Winslow S, Leandersson K, Larsson C. Regulation of PMP22 mRNA by G3BP1 affects cell proliferation in breast cancer cells. Mol Cancer 2013; 12: 156.
24. Fledrich R, Schlotter-Weigel B, Schnizer TJ, Wichert SP, Stassart RM, Meyer ZU, et al. A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients. Brain 2012; 135: 72-87.
25. Verhamme C, King RH, ten Asbroek AL, Muddle JR, Nourallah M, Wolterman R, et al. Myelin and axon pathology in a long-term study of PMP22-overexpressingmice. In J Neuropathol Exp Neurol 2011; 70: 386-98.
26. Meyer zu Horste G, Miesbach TA, Muller JI, Fledrich R, Stassart RM, Kieseier BC, et al. The Wlds transgene reduces axon loss in a Charcot-Marie-Tooth disease 1A rat model and nicotinamide delays post-traumatic axonal degeneration. Neurobiol Dis 2011; 42: 1-8.
27. Pesaresi M, Giatti S, Calabrese D, Maschi O, Caruso D, Melcangi RC. Dihydroprogesterone increases the gene expression of myelin basic protein in spinal cord of diabetic rats. J Mol Neurosci 2010; 42: 135-9.
28. Sung-Wook J, Lopez-Anido C, Ryan M, John S, James I. Identification of DrugModulators Targeting Gene-Dosage Disease CMT1A ACS Chem. Biol 2012; 7: 1205-13.
29. Saporta MA, Shy BR, Patzko A, Bai Y, Pennuto M, Ferri C, et al. MpzR98C arrests Schwann cell development in a mouse model of early-onset Charcot-Marie-Tooth disease type 1B. Brain 2012; 135: 2032-47
30. Dyck PJ, Lais AC, Offord KP. The nature of myelinated nerve fiber degeneration in dominantly inherited hypertrophic neuropathy. Mayo Clin Proc 1974; 49: 34-9.
31. Sahenk Z, Chen L, Freimer M. A novel PMP22 point mutation causing HNPP phenotype: studies on nerve xenografts. Neurology 1998; 51: 702-7.
32. Sahenk Z, Nagaraja HN, McCracken BS, King WM, Freimer ML, Cedarbaum JM, et al: NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology 2005; 65: 681-9.
33. Chan JR, Cosgaya JM, Wu YJ, Shooter EM. Neurotrophins are key mediators of the myelination program in the peripheral nervous system. Proc Natl Acad Sci 2001; 14661-8.
34. Sahenk Z, Galloway G, Edwards C, Malik V, Kaspar BK, Eagle A. TrkB and TrkC agonist antibodies improve function, electrophysiologic and pathologic features in Trembler J mice. Exp Neurol 2010; 224: 495-506.
35. Sahenk Z, Galloway G, Clark KR, Malik V, Rodino-Klapac LR, Kaspar BK, et al. AAV1.NT-3 Gene Therapy for Charcot-Marie-Tooth Neuropathy. Mol Ther 2014; 22: 511-21.